Ma Q - Search Results

1

Antiretroviral Therapy Intensification for Neurocognitive Impairment in Human Immunodeficiency Virus.

Letendre SL, Chen H, McKhann A, Roa J, Vecchio A, Daar ES, Berzins B, Hunt PW, Marra CM, Campbell TB, Coombs RW, Ma Q, Swaminathan S, Macatangay BJC, Morse GD, Miller T, Rusin D, Greninger AL, Ha B, Alston-Smith B, Robertson K, Paul R, Spudich S; A5324 Study Team. Letendre SL, et al. Among authors: ma q. Clin Infect Dis. 2023 Sep 18;77(6):866-874. doi: 10.1093/cid/ciad265. Clin Infect Dis. 2023. PMID: 37183889 Free PMC article. Clinical Trial.

2

Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring.

Slish JC, Catanzaro LM, Ma Q, Okusanya OO, Demeter L, Albrecht M, Morse GD. Slish JC, et al. Among authors: ma q. Curr Pharm Des. 2006;12(9):1129-45. doi: 10.2174/138161206776055787. Curr Pharm Des. 2006. PMID: 16515491 Review.

3

Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.

Ma Q, Brazeau D, Zingman BS, Reichman RC, Fischl MA, Gripshover BM, Venuto CS, Slish JC, DiFrancesco R, Forrest A, Morse GD. Ma Q, et al. Pharmacogenomics. 2007 Mar;8(3):227-35. doi: 10.2217/14622416.8.3.227. Pharmacogenomics. 2007. PMID: 17324111

4

Drug interactions between proton pump inhibitors and antiretroviral drugs.

McCabe SM, Smith PF, Ma Q, Morse GD. McCabe SM, et al. Among authors: ma q. Expert Opin Drug Metab Toxicol. 2007 Apr;3(2):197-207. doi: 10.1517/17425255.3.2.197. Expert Opin Drug Metab Toxicol. 2007. PMID: 17428151 Review.

5

HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries.

Maponga CC, Ma Q, Slish JC, Morse GD. Maponga CC, et al. Among authors: ma q. Top HIV Med. 2007 Jun-Jul;15(3):104-10. Top HIV Med. 2007. PMID: 17598930 Review.

6

Advances in pharmacogenomics of antiretrovirals: an update.

Ma Q, Brazeau D, Forrest A, Morse GD. Ma Q, et al. Pharmacogenomics. 2007 Sep;8(9):1169-78. doi: 10.2217/14622416.8.9.1169. Pharmacogenomics. 2007. PMID: 17924832 Review.

7

Antiretroviral therapy : pharmacokinetic considerations in patients with renal or hepatic impairment.

McCabe SM, Ma Q, Slish JC, Catanzaro LM, Sheth N, DiCenzo R, Morse GD. McCabe SM, et al. Among authors: ma q. Clin Pharmacokinet. 2008;47(3):153-72. doi: 10.2165/00003088-200847030-00002. Clin Pharmacokinet. 2008. PMID: 18307370 Review.

8

Pharmacogenomics of CYP3A: considerations for HIV treatment.

Lakhman SS, Ma Q, Morse GD. Lakhman SS, et al. Among authors: ma q. Pharmacogenomics. 2009 Aug;10(8):1323-39. doi: 10.2217/pgs.09.53. Pharmacogenomics. 2009. PMID: 19663676 Free PMC article. Review.

9

Lack of clinically significant drug interactions between nevirapine and buprenorphine.

McCance-Katz EF, Moody DE, Morse GD, Ma Q, Rainey PM. McCance-Katz EF, et al. Among authors: ma q. Am J Addict. 2010 Jan-Feb;19(1):30-7. doi: 10.1111/j.1521-0391.2009.00006.x. Am J Addict. 2010. PMID: 20132119 Free PMC article.

10

Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir.

Bruce RD, Altice FL, Moody DE, Morse GD, Andrews L, Lin SN, Fang WB, Ma Q, Friedland GH. Bruce RD, et al. Among authors: ma q. J Acquir Immune Defic Syndr. 2010 Aug;54(5):511-4. doi: 10.1097/qai.0b013e3181d3cad3. J Acquir Immune Defic Syndr. 2010. PMID: 20672450 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10,487 results

Search Page

Filters